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Abstract The predictive value of thymidylate synthase (TS)
expression alone for 5FU-based treatment of colorectal cancer
(CRC) has not been clinically confirmed. Little is known on
the association of expression of E2F1, which controls the
transcription of genes encoding proteins engaged in DNA
synthesis including TS, and survival of patients with CRC.
The purpose of this study is to assess the correlation between
expression of both E2F1 and TS in CRCs and survival of
patients administered adjuvant 5FU-based chemotherapy, in
order to find a better predictor of treatment outcome than
expression of TS or E2F1 alone. Nuclear TS and E2F1 were
detected by immunohistochemistry in tissue microarrays from
190 CRCs (Astler-Coller stage B2 or C). Multivariate analysis
identified significant association of the combined E2F1+TS+
immunophenotype with worse OS (HR=3,78, P=0,009) and
DFS (HR= 2,30, P= 0,03) of patients with colon cancer.
There were significant differences between E2F1+TS+ and
E2F1-TS- Kaplan-Meier survival curves in relation to DFS
(P=0.008) and OS (P=0.01). About 37 and 31 % difference
in 3-year DFS and OS respectively were seen between patients
w i t h E 2F 1+TS+ v s . E 2F 1 - TS - c o l o n c a n c e r
immunophenotype. The E2F1+TS+ immunophenotype may
be a marker of poor prognosis (the worst DFS and OS) of
patients with colon cancer treated with 5FU-based adjuvant
therapy. A subgroup of patients with this immunophenotype
may require different and perhaps more aggressive treatment
than 5FU-based chemotherapy. Thus, the combined E2F1/TS
immunophenotype could be a potential indicator of colon can-
cer sensitivity to 5FU.
Keywords Colorectal cancer . E2F1 .Thymidylate synthase .
5FU-based therapy
Introduction
Adjuvant 5-fluorouracil (5FU)-based chemotherapy in stage
III colorectal cancer (CRC) decreases the frequency of cancer
relapse and reduces the risk of cancer associated deaths by
30 % [1, 2]. In stage II colorectal cancer, the benefit of adju-
vant chemotherapy is smaller, improving the 5-year survival
rate by 3–6 % [3]. In advanced CRC approximately 23 % of
patients will respond to 5FU treatment combined with
leucovorin [4]. It follows that a sizable percentage of CRC
patients will not benefit from adjuvant 5FU-based therapy
but will experience toxic side effects of the therapy and un-
necessary costs [5]. Therefore, it is essential to know precisely
which patients will respond to this kind of therapy.
5-fluorouracil has been used in cancer treatment for
the past 40 years. 5FU is an uracil analog and a pro-
drug [6], which undergoes a biotransformation to
pharmacologically-active metabolites. The main target
of 5FU is thymidylate synthase (TS) because 5-
fluorodeoxyuridine-5′-monophosphate (FdUMP), a 5FU
metabolite, binds TS and forms a stable ternary complex
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that prevents DNA synthesis [6]. Studies using CRC
cell lines have suggested the predictive importance of
TS expression with regard to 5FU-based chemotherapy
[7]. However, clinical trials of predictive/prognostic sig-
nificance of TS in CRC patients have reported discrep-
ant findings [8–10]. Therefore it was concluded that TS
expression alone could not be used in clinical practice
as a predictive marker [11]. Recent findings clearly in-
dicate that markers associated with the cell cycle can
help to identify subgroups of CRCs sensitive to 5FU
treatment [12–14]. The E2F1 transcription factor could
be one of such markers because: (1) it regulates the
expression of TS and other enzymes necessary for
DNA synthesis, (2) deregulation of E2F1 is one of the
initial events in colorectal carcinogenesis [15] and anal-
ysis of protein products of genes associated with carci-
nogenesis can help to clarify their biological role in
CRC, (3) high TS expression in tumor cells may be
induced by E2F1 overexpression [16, 17], (4) E2F1
may bind to the TS gene promoter region [17], (5) high
correlation between TS gene and E2F1 gene expression
was found [18], (6) most CRCs show varying degrees
of E2F1 expression [19].
E2F1 belongs to a family of eight (E2F1-8) transcrip-
tion factors which regulate the cell cycle [20]. The ac-
tivation of E2F transcription factors through their re-
lease from phosphorylated pRB complexes leads to tran-
scription of over 1200 genes [21] including TS and oth-
er genes involved in DNA synthesis [17, 22, 23]. E2F1
overexpression may promote proliferation or enhance
apoptosis depending on the level of E2F1 deregulation
and the cell context background [20].
Very few studies have addressed the issue of E2F1
expression and survival of patients with CRC treated
with chemotherapy. These reports assessed small groups
of patients at various stages of advanced colorectal can-
cer with discrepant results [19, 24]. Hence, on one
hand, the predictive value of assessment of TS expres-
sion alone for 5FU-based treatment of CRC has not
been clinically confirmed. On the other hand, although
E2F1 seems to be one of several potential predictors for
response to 5FU-based therapy, because it controls the
transcription of genes encoding proteins engaged in
DNA synthesis including TS, little is known on the
association of E2F1 protein expression and survival of
patients with CRC.
Therefore, to find a better predictor of treatment out-
come than TS or E2F1 alone, the aim of this study was to
assess the correlation between immunohistochemically
determined nuclear expression of both E2F1 and TS in
CRCs and overall survival (OS) and disease free survival




The study group consisted of 190 consecutive patients (mean
age 59.3±10.5) who met the following criteria: (1) had un-
dergone potentially curative colorectal resection for sporadic
CRC (defined as an absence of relevant family history at the
time of admission to the hospital). The surgical operations
consisted of either a resection with lymphadenectomy or a
total mesorectal excision for rectal carcinomas; (2) distant
metastases were excluded on preoperative liver ultrasonogra-
phy, chest X-ray, and during intraoperative exploration; (3)
histopathologic diagnosis of invasive adenocarcinoma
Astler-Coller stage B2 or C without involvement of resection
margins was established; (4) had no chemotherapy prior to the
operation; (5) received identical adjuvant 5FU-based therapy.
All patients received the same adjuvant chemotherapy regi-
men (6 cycles of 5 day courses of 425 mg/m2 5FU adminis-
tered intravenously plus 20 mg/m2 leucovorin). The cycles
were repeated every 4 weeks). A total of 40 patients with
rectal tumors received postoperative radiotherapy (50,4 Gy).
Of the 77 Astler-Coller stage B2 tumors, 36 were rectal can-
cers and, of these, 14 (38.9 %) patients received preoperative
and 10 (27.8 %) received postoperative radiotherapy. Tissues
from the former were obtained from post-therapeutic resection
specimens. Since there were no statistically significant differ-
ences in TS and E2F1 expression between patients with rectal
cancer who did or did not undergo preoperative radiotherapy
[TS (51.6 % vs. 61.3 % respectively, P=0.38), E2F1 (22.6 %
vs. 35.5 % respectively, P=0.24)] the former were included in
the study. Table 1 lists the clinico-pathological characteristics
of the 190 tumors and patients. The Research Ethics
Committee of the Pomeranian Medical University approved
this study (KB-0080/101/09).
The time from surgery until the time of death due to
cancer or to last known follow-up (≥36 months from the
operation) was regarded as OS, and the time until the
first appearance of metastasis or local recurrence was
regarded as DFS. The median follow-up was 51 months
(mean 51.0 ± 23.8; range 7–120). During the follow-up,
44 of the 190 (23.2 %) patients died of cancer.
Recurrences were found in 73 patients. Four patients
died for reasons unrelated to cancer and were treated
as censored observations.
Immunohistochemistry
Tumor tissue was fixed in buffered 10 % formalin and
embedded in paraffin. Sections (4 μm thick) were
stained with hematoxylin and eosin for histopathological
diagnosis. Tissue microarrays (TMs) were constructed as
previously described [13, 14]. Slides with TMs were
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deparaffinized and rehydrated, and endogenous peroxi-
dase activity was blocked. Slides were immersed in pH
9.0 buffer and heat induced antigen retrieval was per-
formed in a pressure cooker (Pascal, DakoCytomation).
Monoclonal TS-106 (Chemicon, Temecula, CA) anti-
body (dilution 1:50, incubation time 30 min) and mono-
clonal E2F1 antibody (Santa Cruz Biotechnology, USA,
dilution 1:100, incubation time 30 min) were used, and
the TMs were immunostained using the Dako Envision
kit according to the manufacturer ’s instructions
(Envision ™ + peroxidase anti-mouse polymer labeled
with horseradish peroxidase – Dako Co., Carpinteria,
CA). The reaction was developed with a diaminobenzi-
dine substrate – chromogen solution and slides were
counterstained with hematoxylin. Appropriate positive
and negative controls were run. The immunohistochem-
ical procedure for all 190 tumors was run at the same
time under identical conditions because tumor tissue
c o r e s w e r e c o n t a i n e d i n o n l y f o u r s l i d e s .
Immunohistochemistry for assessing the presence or ab-
sence of DNA mismatch repair (MMR) proteins was
performed on 180 CRCs (10 tumors could not be
assessed due to insufficient amount of tissue) as de-
scribed in [14]. Immunohistochemistry with antibodies
directed against MMR proteins has been regarded as
an equivalent for microsatellite instability (MSI) testing
[25]. Loss of MMR protein expression was defined as
complete absence of nuclear staining in the presence of
positive staining of stromal cells.
Scoring
Tumor cores were independently assessed by 2 ob-
servers (PD and WD) who were blinded to clinical
and pathological data. In cases of disagreement, the re-
sult was reached by consensus. Semi-quantitative evalu-
ation of immunostained sections was done using well
defined and tested histo-score system [26]. Of three
most frequently applied scoring systems used in the lit-
e ra ture to determine the express ion s ta tus of
immunohistochemically assessed proteins. (i.e., intensity
score, pattern score or both combined), we used inten-
sity & pattern score because it seems to be most reliable
and proved to be useful and reproducible in assessment
of immunohistochemical staining [26–28]. Both intensity
(0–3) and pattern (1–6) scores were assessed. Each in-
tensity score was multiplied by its corresponding pattern
score (1 = 0–4 % of positive tumor cells; 2 = 5–19;
3 = 20–39; 4 = 40–59; 5 = 60–79; 6 = 80–100 %) and
these grades were added to give the final histo–score
(a minimum value of zero and a maximum value of
18). In order to reach the histo-score all tumor cells in
a core of the TM were counted. A histoscore value of 4
was adopted as a cut -off for s t ra t i f ica t ion of
E2F1expression into low (≤4, E2F1-) and high (>4,
E2F1+), because the histogram of E2F1 values showed
a local minimum at this point that clearly divided the
study population into two subgroups. Similarly as in
[14], stratification of TS expression into low (<2, TS-)
and high (≥2, TS+) was based on a local minimum in
the histoscore histogram.
Statistics
Associations between the presence of high TS or E2F1
expression in tumors and other categorical variables
were analyzed with the Fisher exact test. The Kaplan–
Meier method was used for the univariate survival
analysis, and the differences between groups were
assessed by the log-rank test. A Cox proportional haz-
ards model was used for univariate and multivariate
analyses of factors associated with OS and DFS. The
independent variables included in the model were: age,
gender, tumor site (rectum vs. colon), Astler–Coller
stage (C vs. B2), histological grade (G3+mucinous vs.
G1+G2), loss of MMR proteins, presence of high TS
expression and presence of high E2F1 expression. A
p < 0.05 was considered statist ically significant.
STATISTICA version 10 (StatSoft Inc., Tulsa, USA)
was used for the statistical analysis.
Table 1 Characteristics






















a Including mucinous carcinoma
E2F1/TS and survival in colorectal cancer 603
Results
E2F1 and TS Expression and Clinico-Pathologic
Parameters
TS expression (Fig. 1) and E2F1 expression (Fig. 2)
were seen in nuclei of cancer cells. Mean and median
histoscore values were 3.7 and 4.0, respectively for
E2F1, and 4.0 and 3.0, respectively for TS. High TS
(TS+) expression (histoscore TS ≥ 2) in tumor cell nuclei
was noted in 128 out of 190 patients (67.4 %). High
E2F1 (E2F1+) expression (histoscore E2F1>4) was seen
in 36.8 % of patients (70 out of 190 patients). The
E2F1+TS+ immunophenotype was found in 51
(26.8 %) patients, E2F1+TS- in 19 (10.0 %), E2F1-
TS+ in 77 (40.5 %) and E2F1-TS- in 43 (22.6 %) pa-
tients. Loss of MMR proteins was found in 31 out of
180 (17.2 %) CRCs.
We investigated associations of E2F1 and TS expres-
sion with the following parameters: age and gender of
patients, tumor grade, stage, and tumor site. High TS
expression in tumor cell nuclei was seen more often in
tumors located in the colon compared with those in the
rectum (76.8 % vs. 57.9 %, P= 0.008). High E2F1 ex-
pression was more frequent in tumors with B2 stage
compared with C stage (46.8 % vs. 30.1 %, P= 0.02).
It was also more frequent in females than in males
although the difference did not reach statistical signifi-
cance (44.2 % vs. 30.8 %, P = 0.07). There was no
significant association between high E2F1 and high TS
expression (high E2F1 expression was present in
30.7 % of patients with low TS and in 39.8 % of those
with high TS, P= 0.26). There was no significant corre-
lation between MSI status and E2F1/TS positivity
(p= 0.66).
Survival of Patients with CRC Defined by E2F1 and TS
Expression
Multivariate analysis involving sex, age, Astler-Coller stage,
tumor grade, tumor site, loss of MMR proteins and separately
E2F1 and TS expression in all patients (n=180) identified
significant associations only for Astler-Coller stage (C vs.
B2) which was significantly associated with worse DFS
(HR = 3.01, 95 % CI = 1.66–5.46, P = 0.0003) and OS
(HR=3.24, 95 % CI=1.49–7.03, P=0.003), male sex asso-
ciated with worse OS (HR= 2.05, 95 % CI = 1.04–7.03,
P=0.04) and loss ofMMRwhich was significantly associated
with better DFS (HR = 3.71, 95 % CI = 1.74–7.91,
P=0.0007). The association of the loss ofMMR proteins with
OS did not reach statistical significance. However, multivari-
ate analysis (Table 2) involving the above mentioned param-
eters and the combined E2F1+TS+ immunophenotype (high
E2F1 and high TS expression) identified in addition to Astler-
Coller stage (P=0.0001 for DFS and P=0.002 for OS), sex
(p=0.04 for OS), grade (p=0.048 for OS) and loss of MMR
(p = 0.02 for DFS), significant association of E2F1+TS+
immunophenotype with worse OS (HR = 2.35, 95 %
CI = 1.21–4.58, P = 0.01) and DFS (HR = 1.73, 95 %
CI=1.01–2.98, P=0.047).
Because rectal cancers received pre- or postoperative
radiotherapy and colon cancers did not, in order to see
whether the results might depend on the site of the
tumor, patients with tumors localized to the colon and
rectum were analyzed separately.
Colon
Multivariate analysis involving sex, age, Astler-Coller
stage, tumor grade, loss of MMR proteins and separately
E2F1 and TS expression in patients with colon cancerFig. 1 Nuclear expression of TS (brown) in a colon carcinoma
Fig. 2 Nuclear expression of E2F1 (brown) in a colon carcinoma. This is
higher magnification of the upper portion of a core shown in an inset
(lower left corner)
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(n = 90) identified only significant correlation of TS+
(HR = 3.96, 95 % CI = 1.19–13.22, P = 0.03), Astler
Coller C stage (HR = 3.01, 95 % CI = 1.29–7.02,
P=0.01) and loss of MMR proteins (HR=0.20, 95 %
CI=0.04–0.86, P=0.03) with DFS. However, multivariate
analysis involving the above mentioned parameters and the
combined E2F1+TS+ immunophenotype identified signifi-
cant association of E2F1+TS+ immunophenotype with
worse OS (HR=3.78, 95 % CI=1.38–10.33, P=0.009)
and with worse DFS (HR=2.30, 95 % CI=1.08–4.90,
P=0.03) (Table 3). This association remained significant
(OS P=0.006, DFS P=0.02) when only MSI negative
cases were analyzed.
Kaplan-Meier survival curves confirmed the worst DFS
(Fig. 3) and OS (Fig. 4) of patients with colon cancer
exhibiting E2F1+TS+ immunophenotype. There were
significant differences between E2F1+TS+ and E2F1-TS-
curves in relation to DFS (P=0.008) and OS (P=0.01). For
the combined E2F1/TS status, the 3-year DFS rates were 92%
in 13 patients with both low E2F1 and low TS tumors, 55% in
31 patients with both high E2F1 and high TS tumors, 78 % in
9 patients with high E2F1 and low TS tumors and 67 % in 42
patients with low E2F1 and highTS tumors (Fig. 3). For the
combined E2F1/TS status, the 3-year OS rates were 100 % in
13 patients with both low E2F1 and low TS tumors, 69 % in
31 patients with both high E2F1 and high TS tumors, 100% in
9 patients with high E2F1 and low TS tumors and 82 % in 42
patients with low E2F1 and highTS tumors (Fig. 4). About 37
and 31 % diference in 3-year DFS and OS respectively were
seen between patients with E2F1+TS+ colon cancer
immunoph en o t y p e a s c ompa r e d t o E2F1 -TS -
immunophenotype (Figs. 3 and 4).
Table 2 Colorectal cancer.
Multivariate analysis of relations
between expression of E2F1+
TS+1, and other clinico-
pathological parameters, and OS
and DFS (n= 180)
Parameters DFS OS
Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
Male Sex 1.60 0.07 2.03 0.04
0.95–2.68 1.03–3.99
Age 1.01 0.67 1.01 0.97
0.98–1.03 0.97–1.03
Astler-Coller C 3.13 0.0001 3.35 0.002
1.73–5.66 1.55–7.22
Grade G3 1.55 0.09 1.93 0.048
0.94–2.53 1.01–3.68
Site rectum 1.05 0.84 1.03 0.93
0.64–1.74 0.54–1.94
E2F1+TS+ 1.73 0.047 2.35 0.01
1.01–2.98 1.21–4.58
MSI 0.34 0.02 0.48 0.17
0.13–0.85 0.17–1.38
1E2F1+ high expression of E2F1, TS+ high expression of TS
Table 3 Colon cancer.
Multivariate analysis of relations
between expression of E2F1+
TS+1, and other clinico-
pathological parameters, and OS
and DFS (n= 90)
Parameters DFS OS
Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
Male sex 1.54 0.27 2.29 0.11
0.72–3.30 0.82–6.41
Age 1.10 0.63 1.00 0.88
0.97–1.04 0.96–1.05
Astler-Coller C 2.77 0.02 2.59 0.08
1.19–6.45 0.90–7.42
Grade G3 1.65 0.18 1.18 0.74
0.79–3.44 0.45–3.09
E2F1+TS+ 2.30 0.03 3.78 0.009
1.08–4.90 1.38–10.33
MSI 0.23 0.047 0.19 0.11
0.05–0.98 0.02–1.44
1E2F1+ high expression of E2F1, TS+ high expression of TS
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Rectum
In patients with rectal cancer, (n=90) there was no association
between the E2F1/TS immunophenotype and DFS or OS
(P=0.94 and P=0.76 respectively for multivariate analysis).
There was significant interaction between the site of
the tumor (colon vs. rectum) and the E2F1+TS+
immunophenotype with regard to an association with
OS (P = 0.047) but significance of interaction was not
achieved with regard to DFS (P=0.15) in multivariate analy-
sis. These findings indicate that only patients with colon can-
cer (but not those with rectal cancer) treated with adjuvant
5FU could be stratified into better or worse OS prognostic
subgroups by TS and E2F1 expression.
Discussion
Despite numerous studies and clinical trials analysing
predictive/prognostic significance of TS in CRC patients, TS
expression alone has not been recommended in clinical prac-
tice as a predictive marker of 5FU-based treatment [11].
However, recent report clearly indicates that TS in combina-
tion with important regulators of the cell cycle (p53, p21WAF1)
can better identify subgroups of CRCs sensitive to 5FU treat-
ment than TS alone [14]. For reasons explained in the
Introduction we hypothesized that the E2F1 transcription fac-
tor, as important cell cycle associated protein, together with
TS could be a better predictor of treatment outcome than TS or
E2F1 alone. It has been shown that E2F1-overexpressing cells
had increased TS expression and experimental studies indicat-
ed that E2F1 induces various genes associated with S phase,
including TS [16, 17].
In the present study we have compared E2F1/TS
immunophenotype of CRCs with survival of patients treated
with 5FU-based therapy. The results suggest that high E2F1
expression when combined with high TS expression predicts
poor prognosis of patients with colon cancer treated with 5FU-
based regimen. E2F1+TS+ immunophenotype was associated
with poor DFS and OS whereas E2F1-TS- immunophenotype
was associated with excellent survival. It seems that the worst
survival of patients with colon cancer treated with 5FU-based
regimen and exhibiting high TS expression may be attributed
to TS expression induced by high level of E2F1 (E2F1+TS+
immunophenotype). Thus, our results are in line with studies
which found that high E2F1 expression in CRC cell lines was
associated with low sensitivity to 5FU [29, 30] and that high
TS expression was associated with 5FU resistance [31].
Generally, irrespective of E2F1 expression, tumors exhibiting
high TS expression in our study were refractory to treatment
with 5FU-based therapy. However, some TS+ tumors were
E2F1+ and others were E2F1- indicating different mecha-
nisms used by tumor cells to increase TS level and acquire
resistance to treatment.
E2F1’s transcriptional regulation and responses of its
downstream targets constitute a complex issue. E2F1 levels
are dynamically and differentially regulated during the cell
cycle because E2F1 promoter is equipped with sites for both
repression and activation [32]. Therefore, E2F1 may act as an
oncogene or a tumor suppressor depending on tumor cell con-
text i.e., E2F1 is mediating either cell proliferation and growth
or tumor suppresion and apoptosis [20, 33, 34]. Although
E2F1 induces apoptosis and decreased proliferation in cell
lines [35, 36] and tumor tissue in CRCs [37], there is evidence
that high E2F1 expression may be associated with CRC pro-
gression and metastasis [18, 38, 39]. Perhaps, in order to pro-
mote apoptosis or proliferation and survival of cells, different
threshold levels of E2F1 are required for differential gene
transactivation of its target gene promoters [20]. We speculate
Fig. 3 DFS of patients with colon cancer (n= 95) treated with adjuvant
chemotherapy, categorized according to the E2F1/TS expression. E2F1+
TS+ curve differs significantly from E2F1-TS- curve (P= 0.008) but not
from the other curves (P = 0.12; P = 0.18; for E2F1+TS-, E2F1-TS+
curves respectively)
Fig. 4 OS of patients with colon cancer (n= 95) treated with adjuvant
chemotherapy, categorized according to the E2F1/TS expression. E2F1+
TS+ curve differs significantly from E2F1-TS- curve (P= 0.01) and from
E2F1+TS- curve (P= 0.049) but not from E2F1-TS+ curve (P= 0.07)
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therefore that somewhat better survival of patients with tumors
exhibiting E2F1+TS- immunophenotype, as compared to the
worst survival associated with E2F1+TS+ immunophenotype,
may reflect dual activity of E2F1 and point to the important role
of increased TS expression which when induced by E2F1 may
promote proliferation of tumor cells and resistance to 5FU-
based treatment. E2F1 overexpressing human fibrosarcoma
cells in culture had increased TS levels and were resistant to
5FU [16], which is consistent with colon cancers exhibiting
E2F1+TS+ immunophenotype in our study. Interestingly,
Banerjee et al. [16] have shown that cells overexpressing
E2F1 were more sensitive to etoposide, doxorubicin, and SN-
38, the active metabolite of irinotecan, despite being resistant to
5FU. It has to be shown whether colon cancers with E2F1+TS+
immunophenotype, may behave smilarly i.e., may be more sen-
sitive to topo I inhibitors. There are only a few reports on the
association between E2F1 expression alone and survival in
CRC patients. These studies were based on small heterogeneous
groups of patients and yielded conflicting results [19, 24].
TS is one of the basic enzymes participating in DNA syn-
thesis, and serves as the molecular target for 5FU [6]. The
results of studies on prognostic/predictive significance of TS
expression alone in patients with CRC have been inconsistent
and contradictory [11]. It has been suggested that resistance to
5FU chemotherapy cannot be assigned solely to TS or p53
expression [40] rather, markers associated with the cell cycle
should be included in the search for predictive markers of
benefit for 5FU-based chemotherapy in CRC [12]. As part
of its important role in the cell cycle regulation, E2F1 activates
the TS promoter and therefore it may influence the results of
5FU-based treatment of CRC [17, 22].
There is only one report in the literature in which expres-
sion of TS mRNA and E2F1 mRNA were compared in the
same CRCs [18]. In that study increased E2F1 and TSmRNA
expression was noted in 14 % of 23 CRCs. We found high
expression of both E2F1 and TS protein in 27 % of 190 CRCs
but we noted intertumoral heterogeneity with respect to the
combined E2F1/TS immunophenotype. An association of
E2F1 expression with the level of TS was found in primary
[18] and metastatic CRCs [39]. However, in another report
based on 17 primary CRCs the level of E2F1 protein expres-
sion did not correlate with TS expression [24]. The results of
our study suggest that this may be the result of intertumoral
heterogeneity of E2F1/TS immunophenotype.
We did not find an association between E2F1/TS
immunophenotype and OS or DFS of patients with rectal can-
cer. Although there were no statistically significant differences
in TS and E2F1 expression between patients with rectal cancer
who did or did not undergo preoperative radiotherapy, one
cannot exclude the influence of preoperative radiotherapy on
the expression of E2F1 and E2F1-dependent genes including
TS. This aspect requires further study. We would like to men-
tion also some limitations of this study. Although all patients
received the same type of adjuvant chemotherapy, the series of
patients in our study is relatively small and heterogenous.
However, the associations we found were strong and highly
significant.
We conclude that the E2F1+TS+ immunophenotype may be
a marker of poor prognosis (the worst DFS and OS) in patients
with colon cancer treated with 5FU-based adjuvant therapy. It
seems that subgroup of patients with this immunophenotype
may require different and perhaps more aggressive treatment
than 5FU-based chemotherapy. Thus, the combined E2F1/TS
immunophenotype could be a potential indicator of colon can-
cer sensitivity to 5FU. Our results also suggest that one way to
improve the results of treatment of TS+ colon cancer may be to
look for drugs targeting E2F1 or downstream genes of E2F1
other than TS. However, our results are based on a retrospective
study and require confirmation on larger number of colon can-
cer patients and in prospective randomized trials.
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